Neovasculogenic Therapy to Augment Perfusion and Preserve Viability in Ischemic Cardiomyopathy

Pavan Atluri, George P. Liao, Corinna M. Panlilio, Vivian M. Hsu, Matthew J. Leskowitz, Kevin J. Morine, Jeffrey E. Cohen, Mark F. Berry, Erik E. Suarez, Danielle A. Murphy, William M.F. Lee, Timothy J. Gardner, H. Lee Sweeney, Y. Joseph Woo

Research output: Contribution to journalArticlepeer-review

29 Scopus citations

Abstract

Background: Ischemic cardiomyopathy is a global health concern with limited therapy. We recently described endogenous revascularization utilizing granulocyte-macrophage colony stimulating factor (GMCSF) to induce endothelial progenitor cell (EPC) production and intramyocardial stromal cell-derived factor-1α (SDF) as a specific EPC chemokine. The EPC-mediated neovascularization and enhancement of myocardial function was observed. In this study we examined the regional biologic mechanisms underlying this therapy. Methods: Lewis rats underwent left anterior descending coronary artery (LAD) ligation and developed ischemic cardiomyopathy over 6 weeks. Three weeks after ligation, the animals received either subcutaneous GMCSF and intramyocardial SDF injections or saline injections as control. Six weeks after LAD ligation circulating EPC density was studied by flow cytometry. Quadruple immunofluorescent vessel staining for mature, proliferating vasculature was performed. Confocal angiography was utilized to identify fluorescein lectin-lined vessels to assess perfusion. Ischemia reversal was studied by measuring myocardial adenosine triphosphate (ATP) levels. Myocardial viability was assayed by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling detection of apoptosis and quantitation of myofilament density. Results: The GMCSF/SDF therapy enhanced circulating leukocyte (13.1 ± 4.5 × 106 vs 3.1 ± 0.5 × 106/cc, p = 0.001, n = 6) and EPC (14.2 ± 6.6 vs 2.2 ± 2.1/cc, p = 0.001, n = 6) concentrations. Tetraimmunofluorescent labeling demonstrated enhanced stable vasculature with this therapy (39.2 ± 8.1 vs 25.4 ± 5.1%, p = 0.006, n = 7). Enhanced perfusion was shown by confocal microangiography of borderzone lectin-labeled vessels (28.2 ± 5.4 vs 11.5 ± 3.0 vessels/high power field [hpf], p = 0.00001, n = 10). Ischemia reversal was demonstrated by enhanced cellular ATP levels in the GMCSF/SDF borderzone myocardium (102.5 ± 31.0 vs 26.9 ± 4.1 nmol/g, p = 0.008, n = 5). Borderzone cardiomyocyte viability was noted by decreased apoptosis (3.2 ± 1.4% vs 5.4 ± 1.0%,p = 0.004, n = 10) and enhanced cardiomyocyte density (40.0 ± 5.6 vs 27.0 ± 6 myofilaments/hpf, p = 0.01, n=10). Conclusions: Endogenous revascularization for ischemic cardiomyopathy utilizing GMCSF EPC upregulation and SDF EPC chemokinesis upregulates circulating EPCs, enhances vascular stability, and augments myocardial function by enhancing perfusion, reversing cellular ischemia, and increasing cardiomyocyte viability.

Original languageEnglish (US)
Pages (from-to)1728-1736
Number of pages9
JournalAnnals of Thoracic Surgery
Volume81
Issue number5
DOIs
StatePublished - May 2006

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Neovasculogenic Therapy to Augment Perfusion and Preserve Viability in Ischemic Cardiomyopathy'. Together they form a unique fingerprint.

Cite this